Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lycopene decision delayed

This article was originally published in The Tan Sheet

Executive Summary

FDA will not issue a decision before April 12 on a health claim stating lycopene is an "effective modifier of the risk of certain cancers," law firm Emord & Associates states Feb. 10. The agency was supposed to respond to the petition Dec. 24. Emord filed the petition on behalf of American Longevity in June 2003 (1"The Tan Sheet" June 9, 2003, p. 17)...

You may also be interested in...



Lycopene Health Claim For Cancer Risk Reduction Requested In Petition

There is significant scientific agreement among experts that lycopene is an "effective modifier of the risk of certain cancers," supplement marketer American Longevity states in a June 4 health claim petition to FDA

Genfit Delays NASH Data While It Confers With US FDA On Methodology

Genfit will delay unblinding of data from its nearly complete Phase III study of elafibranor to get insight from the FDA on statistical methods in order to optimize its NDA.

Finance Watch: Revolution Medicines Continues 2020’s Post-IPO Trend

Revolution has just one drug in the clinic, but its focus on KRAS excited IPO investors. Also, Deciphera’s $175m offering leads recent follow-ons and Spruce raises $88m in venture capital.

Topics

UsernamePublicRestriction

Register

PS097872

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel